Paperpal Prime Logo

Expert Opinion on Investigational Drugs : Impact Factor & More

eISSN: 1744-7658pISSN: 1354-3784

Aims and Scope of Expert Opinion on Investigational Drugs

Expert Opinion on Investigational Drugs is a monthly peer-reviewed medical journal covering developments in pharmaceutical research, from animal studies through to early clinical investigation. The journal's scope includes therapeutics in many areas: pulmonary-allergy, dermatology, gastrointestinal, arthritis, infectious disorders, endocrine and metabolic, central and peripheral nervous system, cardiovascular and renal, and oncology. Less

Key Metrics

CiteScore
8.6
H-Index
114
Impact Factor
5 - 10
SJR
Q1Pharmacology
SNIP
1.06
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Opinion on Investigational Drugs

Expert Opinion on Investigational Drugs Journal Specifications

Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1994
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Opinion on Investigational Drugs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Opinion on Investigational Drugs

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.
  • 1 Jul 2026
  • Expert opinion on investigational drugs
Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights
  • 27 Jun 2026
  • Expert Opinion on Investigational Drugs
Odronextamab: a bispecific antibody for follicular lymphoma
  • 26 Jun 2026
  • Expert Opinion on Investigational Drugs
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges
  • 18 Jun 2026
  • Expert Opinion on Investigational Drugs
Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer
  • 18 Jun 2026
  • Expert Opinion on Investigational Drugs
SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors
  • 12 Jun 2026
  • Expert Opinion on Investigational Drugs
Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.
  • 1 Jul 2026
  • Expert opinion on investigational drugs
Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights
  • 27 Jun 2026
  • Expert Opinion on Investigational Drugs
Odronextamab: a bispecific antibody for follicular lymphoma
  • 26 Jun 2026
  • Expert Opinion on Investigational Drugs
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges
  • 18 Jun 2026
  • Expert Opinion on Investigational Drugs
Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer
  • 18 Jun 2026
  • Expert Opinion on Investigational Drugs
SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors
  • 12 Jun 2026
  • Expert Opinion on Investigational Drugs

FAQs on Expert Opinion on Investigational Drugs